Revision of the Sapporo criteria for the antiphospholipid syndrome – Coming to grips with evidence and Thomas Bayes?

• References

• 1 Harris EN, Gharavi AE, Boey ML. et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; ii: 1211-4.
• 2 Cervera R, Khamashta MA, Font J. et al. Morbidity and mortality in systemic lupus erythematosus duringa 5-year period: a multicenter prospective study of 1,000 patients. Medicine 1999; 78: 167-75.
• 3 Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004; 164: 77-82.
• 4 Mok CC, Tang SSK, To CH. et al. Incidence and risk factors of thromboembolism in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 2774-82.
• 5 Galli M, Luciani D, Bertolini G. et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-32.
• 6 McNeil HP, Simpson RJ, Chesterman CN. et al. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotin H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
• 7 Wilson WA, Gharavi AE, Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
• 8 APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-84.
• 9 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 04: 295-306.
• 10 Faden D, Tincani A, Tanzi P. et al. Anti-β2 glycoprotein I antibodies ina general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome Anti-β2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. Eur J Obstet Gynecol Reprod Biol 1997; 73: 37-42.
• 11 Lee RM, Branch DW, Silver RM. Immunoglobulin A anti-β2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol 2001; 185: 748-53.
• 12 Galli M, Luciani D, Bertolini G. et al. Anti-β2-glycoprotein, antiprothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-23.
• 13 Reber G, de Moerloose P. Anti-β2-glycoprotein antibodies - when and how should they be measured. Thromb Res 2004; 114: 527-31.
• 14 Detkova D, Gil-Augado A, Lavilla P. et al. Do antibodies to β2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome?. Lupus 1999; 08: 430-8.
• 15 Obermoser G, Bitterlich W, Kunz F. et al. Clinical significance of anticardiolipin and anti-β2-glycoprotein I antibodies. Int Arch Allergy Immunol 2004; 135: 148-53.